---

Pantoprazole is a proton-pump inhibitor that is commonly prescribed for the treatment of gastroesophageal reflux-related disorders. Acute interstitial nephritis is an uncommon though important side-effect of these classes of drugs. We reported a case with acute interstitial nephritis due to pantoprazole. A 25-year-old woman from Ardabil was admitted to our hospital with the complaint of fever, abdominal pain, icterus, oliguria, nausea and vomiting. In laboratory investigations, she had leukocytosis, microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The patient was diagnosed with sepsis, acute pancreatitis and hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura, and she was treated with broad-spectrum antibiotics, hemodialysis and plasmapheresis. One week after treatment, symptoms were improved, and serum creatinine was decreased. Due to the dyspepsia, pantoprazole was prescribed. Following the administration of pantoprazole, serum creatinine was increased again. Urinalysis revealed pyuria and white blood cell (WBC) cast, and a subsequent renal biopsy confirmed a diagnosis of acute interstitial nephritis. Physicians should be aware that drug-induced acute interstitial nephritis can be associated with proton-pump inhibitors. Early detection of this rare adverse reaction may prevent acute renal failure.

---

Background and purpose: Proton pump inhibitors (PPIs) are one of the main therapeutic agents for acid-dependent diseases. Inappropriate use of this group of drugs especially Intravenous form of pantoprazole can lead to unnecessary cost. The aim of this study was to assess the IV Pantoprazole utilization in a teaching hospital in North of Iran.
Materials and methods: This cross sectional study was performed within four months in 100 patients hospitalized in Ramsar Imam Sajjad Hospital, 2016. Demographic data, type and doses of Pantoprazole, risk factors for stress ulcer, and other relevant clinical data were recorded. Appropriate use of Pantoprazole was assessed according to recommendations provided by Fact Drug Information 2016, Medscape 2016, and UpToDate 2016.
Results: Among the patients 54% had indication for receiving a PPI and only 16% had indication for parenteral form of PPI. Oral PPIs could have been used in 73% of the patients but they received parenteral form of Pantoprazole. In 92% of IV injections, a vial of 40 mg Pantoprazole was dissolved in 10 ml distilled water and injection was done in less than 10 seconds which was incompatible with guidelines.
Conclusion: In current study, utilization of Pantoprazole was not compatible with guidelines in most cases, including right indication, right preparation methods and right rate of drug administration.
 

---

Background and purpose: Proton pump inhibitors (PPIs) are one of the main therapeutic agents for acid-related diseases. Pantoprazole, with minimal drug interaction, is one of the well-known PPIs. According to various studies, 25-75% of pantoprazole injections have no indications and cause a high burden on health systems. The aim of this study was to investigate the indication and rate of pantoprazole injections in Yazd Rahnemoon Hospital, Iran.
Materials and methods: This cross-sectional study was performed in 72 hospitalized patients in invasive care units, and internal and emergency wards between March and December 2019. Demographic and clinical data, risk factors, PPI indication, and doses of utilized pantoprazole were recorded. The rationality of pantoprazole prescription was confirmed by comparing the drug information from up-to-date database under the supervision of a clinical pharmacist in the hospital.
Results: In total, out of 60 patients who received IV pantoprazole, 52.8% could have received the oral form and in 69.4% there was no indication to use IV pantoprazole.
Conclusion: In this study, parenteral form of pantoprazole was not indicated in majority of the patients. Guidelines should be approved to prevent irrational administration of parental PPIs in hospitals.